Tenaya Therapeutics, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 18, 2024. Although the request refers to 2023 Q4, this is an annual filing, and the supplied text does not provide separate fourth-quarter financial results.
Business context
Tenaya is a clinical-stage biotechnology company developing therapies aimed at underlying causes of heart disease. It had no approved products and generated no product revenue in 2023. Its lead programs are TN-201, an AAV9 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, an AAV9 gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, an HDAC6 inhibitor being evaluated for heart failure with preserved ejection fraction (HFpEF).
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $98.0 million | $94.5 million |
| General and administrative expense | $33.2 million | $31.1 million |
| Total operating expenses | $131.2 million | $125.6 million |
| Net loss | $124.1 million | $123.7 million |
| Net cash used in operating activities | $102.1 million | $104.4 million |
There are no revenue-based margins to assess. Operating expenses rose 4%; R&D increased 4% and G&A increased 7%. Higher R&D personnel costs were partly offset by lower outside services, primarily following a reduction in IND-enabling work. Higher G&A was primarily attributed to stock-based compensation. Net loss was nearly unchanged, as increased expenses were largely offset by higher interest income.
At year-end, cash and cash equivalents were $45.7 million and marketable securities were $59.0 million, totaling $104.6 million in cash, cash equivalents and investments. Current assets were $111.6 million and current liabilities $22.7 million. Total liabilities were $31.1 million, including $12.4 million of operating lease liabilities; the filing does not report borrowings or other debt. Accumulated deficit was $403.3 million. Cash, cash equivalents and restricted cash decreased $49.3 million during 2023.
Material changes, outlook and risks
- TN-201’s first patient was dosed in its Phase 1b MyPeak-1 trial in October 2023; initial data were anticipated in the second half of 2024. TN-401 received FDA IND clearance in October 2023, with first patient dosing planned for the second half of 2024.
- TN-301 completed Phase 1 testing in healthy volunteers in 2023. The company reported a generally well-tolerated profile, dose-related target engagement and pharmacokinetics consistent with once-daily dosing. Tenaya is evaluating partnership opportunities and expects a well-resourced partner to lead later-stage development and commercialization.
- Management expected operating expenses to remain relatively flat over the next 12 months. It stated that year-end resources, together with the February 2024 offering proceeds, were expected to fund operations for at least 12 months following filing. Tenaya also expects to need substantial additional capital to complete development and potentially commercialize candidates.
- On February 12, 2024, after year-end, Tenaya raised approximately $46.5 million net through an offering of common stock and pre-funded warrants. Further equity financing could dilute existing holders; collaboration financing could require granting rights to programs.
- Key uncertainties include early-stage clinical evidence and potential safety issues with gene therapy, trial enrollment and execution, manufacturing scale-up and regulatory requirements, competition, intellectual-property disputes, and the ability to secure financing and partnerships. The company reported no material litigation.
Important facts for investors to verify
- TN-201 trial safety, dose response and timing of initial data, and whether findings support further development.
- TN-401’s planned trial start, enrollment progress and safety monitoring.
- Whether Tenaya secures a partner for TN-301 and on what financial and rights terms.
- Cash use and runway after the February 2024 financing, including the impact of ongoing clinical and manufacturing costs.
- Potential dilution from outstanding pre-funded warrants, equity awards and any future financing; 5.9 million pre-funded warrant shares remained outstanding at December 31, 2023.
- Ability to protect key intellectual property and to manufacture gene therapy candidates consistently at clinical and future commercial scale.
The independent auditor issued an unmodified opinion on the financial statements. Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2023; the auditor was not engaged to provide an opinion on internal-control effectiveness.